Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovarian, fallopian, peritoneal cancer

Share :
Published: 24 Sep 2021
Views: 1644
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Dr Susana Banerjee talks to ecancer about the principal results of the EORTC-1508 trial. A phase II randomised, multicentre study of bevacizumab (BEV) vs atezolizumab (ATE) and BEV with acetylsalicylic acid (ASA) or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma.

She begins by explaining that unfortunately, the majority of women eventually develop platinum resistant disease, once disease has recurred. And there remains an unmet need for more effective treatments for platinum resistant ovarian cancer.

Dr Banerjee then goes on to say how the study was carried out in five countries across multiple sites and initially patients were randomised to one of five arms. Patients on the first 3 arms (non-combination) had the opportunity to cross-over to BEV and ATE at progression. However arms 2 and 3 were closed early following phase III results indicating insufficient activity of PD-L1 inhibitor monotherapy.

She concludes that the addition of ASA to BEV+ATE did not improve efficacy. Relative to BEV or ATE(+/-ASA) arms, the BEV+ATE combinations numerically improved PFS and TFST and merits further exploration. Translational analyses are ongoing to identify biomarkers of clinical benefit.